Offline mode

CRP high sensitive (C- reactive protein) ELISA

Buy on the e-shop
Catalog no.30247945
Regulatory Status
EU: CE
Kit size
12x8
Method
ELISA
Incubation time
2x30min, 1x10min
Standard range
0 - 10 µg/mL
Specimen / Volumes
10 µL serum, plasma
Substrate / isotope
TMB 450 nm
instructions for use

Intended use

Enzyme immunoassays for the quantitative high sensitive determination of C-Reactive Protein in human
serum and plasma.

Summary and explanation

C-Reactive Protein (CRP) is an acute-phase protein, produced exclusively in the liver. Interleukin-6 is the mediator for the synthesis by the hepatocytes of CRP, a pentamer of approximately 120.000 Daltons. CRP is present in the serum of normal persons at concentrations ranging up to 5 mg/L.

A series of prospective studies provide consistent data documenting that mild elevation of baseline levels of CRP among apparently healthy individuals is associated with higher long-term risk for future cardiovascular events. This predictive capacity of CRP is independent of traditional cardiovascular risk factors and offers a prognostic advantage over measurement of lipid alone. Inflammatory markers specifically hsCRP may help to identify those who would benefit most from these pharmacological intervention. hsCRP is the novel and evolving biomarker which provides a most useful predictive indicator for subsequent cardiovascular events. This test should not be used for assessment of acute inflammation but should be ordered to evaluate CVD (Cardiovascular Disease) risk in apparently healthy individuals who have not had recent infection or other serious illness.

For the assessment of acute inflammation the IBL-International CRP ELlSA (30247946) can be used.

Distributed by Tecan, IBL International GmbH.

For concrete data please consult the Instruction for Use in the download box on the top right side.

  1. WU A. H.B. Tietz Clinical Guide to Laboratory Tests, fourth edition. Saunders Elsevier (2006): 190.
  2. Mitra B, Panja M. -High sensitive C-reactive protein: a novel biochemical markers and its role in coronary artery disease, J Assoc Physicians India. 2005 Jan; 53:25-32.
  3. KANDA T. C-reactive protein (CRP) in the cardiovascular system, Rinsho Byori, 2001 Apr, 49(4), 395-401.
  4. URSELLA, M.MAZZONE, G.PORTALE, A.TESTA, G.PIGNATARO, M. COVINO, P. FENICI, G.B. GASBARRINI, N. GENTILONI SILVERI. How to use the C-reactive protein in cardiac disease ? Ital Heart J. 2001 Mar; 2(3): 164-171.
  5. KRAUSE KJ. C-reactive protein: a screening test for coronary disease? J Insur Med. 2001, 33(1), 4- 11.
  6. RIDKER PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention, Am J Cardiol, 2003 Aug 21, 92(4B), 17K-22K.
  7. SHAH SH., NEWBY LK. C-reactive protein: a novel marker of cardiovascular risk, Cardiol Rev. 2003 Jul-Aug, 11.

Our Product Families

Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.

And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.

All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use. 

All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).

Image on background

This is who we are.

As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.

Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.

Happy to help.

At Tecan, we are driven to improve people’s lives and health.